Incyte Newsroom

Goldman Sachs Adjusts Price Target on Incyte to $61 From $60, Maintains Neutral Rating

MT NewswiresJul 16 06:27 ET

Incyte Analyst Ratings

BenzingaJul 2 05:17 ET

Incyte Analyst Ratings

BenzingaJun 18 09:47 ET

Analysts' Opinions Are Mixed on These Healthcare Stocks: Biogen (BIIB) and Incyte (INCY)

TipRanksMay 23 07:15 ET

Incyte Analyst Ratings

BenzingaMay 23 07:07 ET

Incyte's Share Buyback Program: A Buy Rating and Fundamental Value Increase

TipRanksMay 16 04:15 ET

Incyte's Strategic Financial Decisions and Market Positioning: A Hold Rating Analysis

TipRanksMay 13 18:50 ET

Analysts Offer Insights on Healthcare Companies: Sanofi (OtherSNYNF), Incyte (INCY) and Ventyx Biosciences (VTYX)

TipRanksMay 10 07:35 ET

Incyte's Resilient Demand and Strong Financials Justify Buy Rating Despite Q1 Sales Dip

TipRanksMay 2 02:20 ET

Analysts Offer Insights on Healthcare Companies: Harmony Biosciences Holdings (HRMY), TransMedics Group (TMDX) and Incyte (INCY)

TipRanksMay 1 08:06 ET

Incyte Analyst Ratings

BenzingaMay 1 08:04 ET

Citigroup Adjusts Price Target on Incyte to $80 From $81

MT NewswiresMay 1 08:00 ET

RBC Capital Reaffirms Their Hold Rating on Incyte (INCY)

TipRanksMay 1 06:40 ET

Analysts Offer Insights on Healthcare Companies: Incyte (INCY) and Exelixis (EXEL)

TipRanksMay 1 00:45 ET

Truist Securities Trims Incyte's Price Target to $83 From $84, Buy Rating Maintained

MT NewswiresApr 30 14:58 ET

Incyte's Strategic Acquisition and Promising Pipeline Secure Buy Rating

TipRanksApr 26 02:21 ET

Oppenheimer Sticks to Its Buy Rating for Incyte (INCY)

TipRanksApr 24 07:51 ET

Incyte Analyst Ratings

BenzingaApr 24 07:27 ET

Incyte Acquisition Strategy and Drug Pipeline Evaluation: A Hold Recommendation

TipRanksApr 24 05:41 ET

Incyte (INCY) Gets a Buy From Piper Sandler

TipRanksApr 23 15:30 ET